TEL AVIV, Israel, November 9, 2017 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ: BLRX) (TASE:
BLRX), a clinical-stage biopharmaceutical company focused on
oncology and immunology, announced today that it will release its
unaudited financial results for the quarter ended September 30, 2017 on Tuesday, November 21, 2017, before the U.S.
markets open.
The Company will host a conference call on Tuesday, November 21, 2017 at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer, and
David Malek, Chief Business Officer.
The conference call will be available via webcast and can be
accessed through the Investor Relations page of BioLineRx's
website. Please allow extra time prior to the call to visit the
site and download any necessary software to listen to the live
broadcast.
To dial into the conference call, please dial 1-888-407-2553
from the U.S. or +972-3-918-0664 internationally. A replay of the
conference call will be available approximately two hours after
completion of the live conference call at the Investor Relations
page of BioLineRx's website. A dial-in replay of the call will be
available until November 24, 2017;
please dial 1-866-500-4953 from the U.S. or +972-3-925-5946
internationally.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company focused
on oncology and immunology. The Company in-licenses novel
compounds, develops them through pre-clinical and/or clinical
stages, and then partners with pharmaceutical companies for
advanced clinical development and/or commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory AML, is in the midst of a Phase 2b
study as an AML consolidation treatment and is expected to initiate
a Phase 3 study in stem cell mobilization for autologous
transplantation; and AGI-134, an immunotherapy treatment in
development for multiple solid tumors, which is expected to
initiate a first-in-man study in the first half of 2018. In
addition, BioLineRx has a strategic collaboration with Novartis for
the co-development of selected Israeli-sourced novel drug
candidates; a collaboration agreement with MSD (known as Merck in
the US and Canada), on the basis
of which the Company has initiated a Phase 2a study in pancreatic
cancer using the combination of BL-8040 and Merck's KEYTRUDA®; and
a collaboration agreement with Genentech, a member of the Roche
Group, to investigate the combination of BL-8040 and Genentech's
atezolizumab in several Phase 1b/2 studies for multiple solid tumor
indications and AML.
For additional information on BioLineRx, please visit the
Company's website at www.biolinerx.com, where you can review the
Company's SEC filings, press releases, announcements and events.
BioLineRx industry updates are also regularly updated on Facebook,
Twitter, and LinkedIn.
Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-212-554-5482
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-3-624-0871
tsipihai5@gmail.com
SOURCE BioLineRx Ltd.